Published in J Cell Mol Med on June 20, 2008
Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest (2009) 1.13
Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther (2014) 0.93
GSK3 regulates mitotic chromosomal alignment through CRMP4. PLoS One (2010) 0.92
Glycogen synthase kinase 3 β activity is required for hBora/Aurora A-mediated mitotic entry. Cell Cycle (2013) 0.89
Knocking down CDK4 mediates the elevation of let-7c suppressing cell growth in nasopharyngeal carcinoma. BMC Cancer (2014) 0.88
GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol (2010) 0.88
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal (2012) 0.81
GSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation. Cell Cycle (2015) 0.75
Lithium Reversibly Inhibits Schwann Cell Proliferation and Differentiation Without Inducing Myelin Loss. Mol Neurobiol (2016) 0.75
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
G1 cell-cycle control and cancer. Nature (2004) 5.72
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol (2000) 5.55
Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer (2007) 4.16
Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci (2004) 3.05
Molecular targets of lithium action. Annu Rev Pharmacol Toxicol (2001) 2.63
Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci (2007) 2.37
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol (2006) 2.17
GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal (2007) 2.11
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell (2002) 1.90
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J Cell Sci (2003) 1.78
The significance of the Wnt pathway in the pathology of human cancers. Pathology (2004) 1.76
Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta (2006) 1.56
Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene (2004) 1.54
Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun (2003) 1.53
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res (2005) 1.51
Targeting GSK-3: a promising approach for cancer therapy? Future Oncol (2006) 1.50
GSK-3 inhibitors induce chromosome instability. BMC Cell Biol (2007) 1.48
The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle (2007) 1.45
Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology (2007) 1.41
Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci (2007) 1.40
SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene (2006) 1.37
Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets (2007) 1.34
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci (2003) 1.32
The E2F-Cdc2 cell-cycle pathway specifically mediates activity deprivation-induced apoptosis of postmitotic neurons. J Neurosci (2003) 1.30
Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol Disord Drug Targets (2007) 1.24
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int J Cancer (2005) 1.20
Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev (2006) 1.17
Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol (2005) 1.14
Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate (2007) 1.14
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiol Aging (2001) 1.06
GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother (2007) 1.04
Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells. J Biol Chem (2001) 1.04
CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int (2007) 1.02
Glycogen synthase kinase-3 beta; a new target in pancreatic cancer? Curr Cancer Drug Targets (2007) 0.97
Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem (2007) 0.96
Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun (2002) 0.96
Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord (2005) 0.89
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 0.89
Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother (2006) 0.87
The cell cycle and hormonal fluxes in Alzheimer disease: a novel therapeutic target. Curr Pharm Des (2006) 0.86
Molecular and biochemical features in Alzheimer's disease. Curr Pharm Des (2006) 0.86
Cdh1-APC/C, cyclin B-Cdc2, and Alzheimer's disease pathology. Biochem Biophys Res Commun (2005) 0.85
Inhibition of cell proliferation by lithium is associated with interference in cdc2 activation. FEBS Lett (1999) 0.83
Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology (2007) 0.82
Lithium induces morphological differentiation of mouse neuroblastoma cells. J Neurosci Res (1999) 0.82
Rotenone induces disassembly of the Golgi apparatus in the rat dopaminergic neuroblastoma B65 cell line. Neurosci Lett (2004) 0.78
Lithium increases expression of p21(WAF/Cip1) and survivin in human glioblastoma cells. Cell Biol Toxicol (2006) 0.78
The sequence of the human genome. Science (2001) 101.55
The impact of patient-centered care on outcomes. J Fam Pract (2000) 15.07
Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats. JAMA (1996) 4.71
A potent pressor response elicited by drinking water. Lancet (1999) 3.02
Preemption in tobacco control. Review of an emerging public health problem. JAMA (1997) 2.67
Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med (2000) 2.53
Physicians' attitudes about involvement in lethal injection for capital punishment. Arch Intern Med (2000) 2.04
Bordetella holmesii sepsis in an asplenic adolescent. Pediatr Infect Dis J (1995) 2.03
Characterization of Giemsa dark- and light-band DNA. Cell (1982) 1.96
The 1972 Cuban national child growth study as an example of population health monitoring: design and methods. Ann Hum Biol (1975) 1.94
Confirming positive results of nucleic acid amplification tests (NAATs) for Chlamydia trachomatis: all NAATs are not created equal. J Clin Microbiol (2005) 1.88
European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol (2010) 1.86
Mycoplasma pneumoniae protein P30 is required for cytadherence and associated with proper cell development. J Bacteriol (1999) 1.62
A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta (1980) 1.58
Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis (2000) 1.55
A randomized control trial of two cervical spatulas. Br J Obstet Gynaecol (1991) 1.50
Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric (2008) 1.49
Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol (2005) 1.43
The 6-week postnatal visit: are we doing it right? Br J Hosp Med (1995) 1.42
Allergen challenge increases anandamide in bronchoalveolar fluid of patients with allergic asthma. Clin Pharmacol Ther (2011) 1.41
Sympathetically mediated hypertension in autonomic failure. Circulation (2000) 1.29
Altered autonomic support of arterial blood pressure with age in healthy men. Circulation (2001) 1.28
The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol (2011) 1.27
Structural analysis of the glycine-rich, arginine-rich histone. 3. Sequence of the amino-terminal half of the molecule containing the modified lysine residues and the total sequence. J Biol Chem (1969) 1.21
Characterization of Centers for Disease Control group NO-1, a fastidious, nonoxidative, gram-negative organism associated with dog and cat bites. J Clin Microbiol (1993) 1.20
Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res (2009) 1.20
Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol (2013) 1.20
The hypertension of autonomic failure and its treatment. Hypertension (1997) 1.18
Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev (2006) 1.17
Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current. Neurology (2007) 1.16
Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest (1984) 1.15
Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorg Med Chem (2008) 1.14
HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr (2000) 1.14
Modern concepts in antiglaucomatous implant surgery. Graefes Arch Clin Exp Ophthalmol (2008) 1.13
Koilocytes and cervical human papillomavirus infection. Lancet (1986) 1.11
Heart failure due to enlarged tonsils and adenoids. The cardiorespiratory syndrome of increased airway resistance. Am J Dis Child (1969) 1.11
Family medicine in a tertiary care hospital. Obstetrical outcomes and interventions. Can Fam Physician (1995) 1.10
Making sense of health needs assessment. Br J Gen Pract (1997) 1.10
European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology (2007) 1.09
Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci (1997) 1.09
Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet (1988) 1.06
From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis (2008) 1.04
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem (2008) 1.03
"Sitting in different chairs:" roles of the community health workers in the Poder es Salud/Power for Health Project. Educ Health (Abingdon) (2008) 1.02
Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol (2006) 1.02
Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. Neurotox Res (2011) 1.01
Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.01
Genetic influences on baroreflex function in normal twins. Hypertension (2001) 1.01
Aging biology: a new frontier for drug discovery. Expert Opin Drug Discov (2012) 1.01
Cell-mediated immunity to human pancreas in diabetes mellitus. Diabetes (1974) 1.01
Phytohaemagglutinin-induced lymphocyte transformation and circulating autoantibodies in women taking oral contraceptives. Lancet (1974) 1.01
The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect (2006) 1.00
Early amyloid accumulation in the hippocampus of SAMP8 mice. J Alzheimers Dis (2010) 1.00
Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol Appl Pharmacol (2004) 0.99
Cell-mediated immunity in diabetes mellitus; lymphocyte transformation by insulin and insulin fragments in insulin-treated and newly-diagnosed diabetes. Diabetes (1975) 0.99
Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol (2005) 0.98
Osmosensitive mechanisms contribute to the water drinking-induced pressor response in humans. Neurology (2005) 0.98
Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr) (2012) 0.96
Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging (2011) 0.96
Adherence to combined Lamivudine + Zidovudine versus individual components: a community-based retrospective medicaid claims analysis. AIDS Care (2005) 0.96
Neurophysiological and epigenetic effects of physical exercise on the aging process. Ageing Res Rev (2011) 0.95
Effects of standing on cerebrovascular resistance in patients with idiopathic orthostatic intolerance. Am J Med (1999) 0.95
Retinal tolerance to dyes. Br J Ophthalmol (2005) 0.93
Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry. Neuroreport (2002) 0.92
Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment. J Pharmacol Exp Ther (2003) 0.92
Recombinant human interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS (1997) 0.92
Phytohemagglutin-induced lymphocyte transformation in oral contraceptive users. Obstet Gynecol (1977) 0.92
Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev (2007) 0.91
Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov (2008) 0.91
Elevated oxidative stress in the brain of senescence-accelerated mice at 5 months of age. Biogerontology (2006) 0.91
Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J Neurovirol (2003) 0.91
Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res (2006) 0.90
Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann N Y Acad Sci (2001) 0.90
Differences in activation of ERK1/2 and p38 kinase in Jnk3 null mice following KA treatment. J Neurochem (2010) 0.90
Sirtuin activators: designing molecules to extend life span. Biochim Biophys Acta (2010) 0.89
A new method for determining blood-brain barrier integrity based on intracardiac perfusion of an Evans Blue-Hoechst cocktail. J Neurosci Methods (2008) 0.89
Norepinephrine transporter function and human cardiovascular disease. Am J Physiol Heart Circ Physiol (2012) 0.89
Particle-size dependent effects in the Balb/c murine model of inhalational melioidosis. Front Cell Infect Microbiol (2012) 0.89
Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord (2007) 0.89
Phosphatase inhibitors--III. Benzylaminophosphonic acids as potent inhibitors of human prostatic acid phosphatase. Bioorg Med Chem (1996) 0.89
Uncoupling of the baroreflex by N(N)-cholinergic blockade in dissecting the components of cardiovascular regulation. Hypertension (1998) 0.88